To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
From Promise to Productivity: Smart Policy for Sustainable EU Growth Through Biobased Products and Industrial Biotechnology
15-10-2012: EuropaBio warmly welcomes the European Commission’s new proposal on industrial policy for growth and economic recovery. Launched by Vice President Tajani, following extensive consultation and analysis, the Communication builds on the work of the Lead Market Initiative (LMI) and highlights biobased product markets as one of six key priority action lines with the greatest potential for delivering new products and for increasing productivity. In addition, markets for Key Enabling Technologies (KETs), including Industrial Biotech, are highlighted as another of the six priority action lines destined for greater uptake through member state technology policies and European Innovation Partnerships (EIPs).
Commenting on the Communication, Joanna Dupont-Inglis, Director for Industrial Biotech at EuropaBio said: “We are delighted to see not only priority action lines on markets for KETs but also for biobased products, reflecting the real potential of this sector. The alignment of the six priority actions with sectors for smart specialisation, defined for cohesion policy in the member states, is also an important aspect.”
The Communication highlights the key role of Public Private Partnerships (PPPs) for Europe as a way of strengthening competitiveness, laying the foundations for the reindustrialisation of the economy, eliminating bottlenecks and getting innovation to market faster across the EU. The importance of proposals for a Sustainable Process Industry PPP (SPIRE) and for a Biobased Industries PPP are also emphasised.
Lars Hansen, Chair of EuropaBio’s Industrial Biotech Council and President of Novozymes Europe summed up “Industrial biotech has been clearly identified by this communication as one of Europe’s leading technologies poised to deliver smart and sustainable jobs and growth. The good news is that the gap remaining between high tech research and innovative, commercial competitiveness can be bridged to deliver the kind of economic recovery we need to see and feel. Investments in biorefinery demonstration facilities, through initiatives such as SPIRE and BioBased Industries PPPs, are now of paramount importance in order to develop thriving biobased product markets. For that, we need collective commitment and timely implementation of the joined-up policy making outlined by today’s Communication.”
- 1Why stem cells need to stick with their friends
- 2Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 3Panspecific antibodies: Novimmune successful in multiple specificities
- 4Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 5Takara Bio to Acquire Clontech Unit of BD Biosciences
- 6Oxford BioMedica has appointed Martin Diggle as a non-executive director
- 7Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 8Novirio Pharmaceuticals Limited Becomes Idenix Pharmaceuticals , Inc.
- 9Bayer acquires exclusive rights to Bioton’s insulin SciLin
- 10BASF Fine Chemicals Switzerland SA and BASF Orgamol Pharma Solutions SA merger announced
- UK Agency’s Update on “Three-Person IVF” Leaves Safety Questions Unresolved
- European Medicines Agency update on stolen vials of Herceptin
- EMA alerts EU healthcare professionals after vials of falsified Herceptin id ...
- Update on infringement procedure against Roche Registration Ltd.
- Recommendation against combined use of medicines affecting the renin-angiote ...
- Ablynx successfully raises €41.7 million
- First Clinical Trial in Allogeneic Bone Cell Therapy Product
- BioCartis receives € 1,7M IWT grant for improved disease diagnosis
- New blood test identifies risk “Sudden Cardiac Death”
- Ablynx's anti-vWF Nanobody achieves clinical proof-of-concept in Phase II TITAN study